Pfizer Announces $4.9 Billion Acquisition of Obesity Drug Developer Metsera
Pfizer plans to acquire obesity and heart disease drug company Metsera for $4.9 billion, aiming to strengthen its position in the growing obesity treatment market amid industry competition.
In a strategic move to expand its presence in the rapidly growing market for obesity treatment, pharmaceutical giant Pfizer has agreed to acquire Metsera, a company specializing in medications for obesity and cardiovascular conditions, for $4.9 billion. This acquisition aims to position Pfizer as a key player in the lucrative obesity and related health condition sectors.
The deal, which involves Pfizer purchasing all outstanding shares of Metsera at $47.50 per share, is anticipated to close in the final quarter of 2025. The move follows a broader industry trend where major pharmaceutical companies are investing heavily in obesity and diabetes therapeutics, motivated by the success of drugs like Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Zepbound.
Pfizer CEO Albert Bourla highlighted the strategic importance of this investment, stating that obesity is a substantial and expanding health issue with over 200 associated conditions. He emphasized that the acquisition aligns with Pfizer’s goal to focus on impactful therapeutic areas.
This acquisition also comes at a time when Pfizer’s stock has faced fluctuations since the end of the COVID-19 pandemic, with its share price dropping from $58 in December 2021 to around $24 recently. Notably, in pre-market trading on Monday, Pfizer's stock rose by 1.6%, while Metsera's shares surged by 60%, indicating strong investor optimism.
The move marks Pfizer’s entrance into a highly competitive market, where the demand for effective obesity treatments continues to grow, driven by increasing global health concerns. Industry experts observe that Pfizer's entry could intensify competition and innovation in this segment.
For more details, visit source: https://medicalxpress.com/news/2025-09-pfizer-obesity-drug-maker-metsera.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Pulsating Microneedles Offer Painless Transdermal Drug Delivery
Emerging pulsating microneedles provide a pain-free, scalable solution for transdermal drug delivery, revolutionizing how medications are administered without traditional needles.
New Study Finds Human Egg Cells Are Shielded From Age-Related Genetic Mutations
Recent research uncovers that human egg cells are safeguarded from accumulating age-related mitochondrial DNA mutations, offering promising insights into reproductive health and aging.
Semaglutide Shows Promise in Protecting Against Diabetic Retinopathy
Emerging research suggests that semaglutide, a GLP-1 receptor agonist, may protect against diabetic retinopathy by reducing oxidative stress and promoting retinal cell repair. This could lead to new treatments for preventing vision loss in diabetics.
FDA Approves Dupixent for Treatment of Bullous Pemphigoid
The FDA has approved Dupixent for adult patients with bullous pemphigoid, offering a new targeted treatment option based on promising clinical trial results that show improved remission and reduced itch.